Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BL22 immunotoxin · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| BL22 immunotoxin | DRUG | - |
| antibody-drug conjugate therapy | PROCEDURE | - |
| immunotoxin therapy | PROCEDURE | - |
DISEASE CHARACTERISTICS: * Diagnosis of B-cell leukemia or lymphoma of 1 of the following types: * Chronic lymphocytic leukemia * Failed standard chemotherapy * Prolymphocytic leukemia * Failed standard chemotherapy * Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma ...
Top 20 of 63 competitors
BL22 immunotoxin is an investigational therapy being studied for the treatment of leukemia, specifically refractory chronic lymphocytic leukemia, prolymphocytic leukemia, and non-Hodgkin's lymphoma. It is a small molecule in Phase 1 clinical development for oncology indications.
BL22 immunotoxin is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting clinical research on this investigational therapy for leukemia and lymphoma indications.
BL22 immunotoxin is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety and efficacy.
BL22 immunotoxin has one completed clinical trial, NCT00126646, which studied the drug in patients with refractory chronic lymphocytic leukemia, prolymphocytic leukemia, or non-Hodgkin's lymphoma. The trial enrolled 24 participants in the United States.
BL22 immunotoxin is the full name of the drug, and it is commonly referred to as BL22. The clinical trial NCT00126646 uses the name BL22 immunotoxin in its title, confirming that both names refer to the same investigational therapy.